Athera Biotechnologies

About:

Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases.

Website: https://athera.se/

Top Investors: Sciety, Industrifonden, Texas Venture Labs, Ostersjöstiftelsen

Description:

Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit.

Total Funding Amount:

136M SEK

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Stockholm, Stockholms Lan, Sweden

Founded Date:

2005-01-01

Contact Email:

info(AT)athera.se

Founders:

Johan Frostegard

Number of Employees:

1-10

Last Funding Date:

2019-04-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai